Back

Epigenetic Regulation of Inflammation by Dopamine in Primary Human Macrophages

Agarwal, Y.; Ramani, M.; Manikandan, S.; Bonar, K.; Montilla, J.; Gaskill, P. J.; Matt, S.

2026-01-23 immunology
10.64898/2026.01.21.700899 bioRxiv
Show abstract

While dopamine is a monoamine neurotransmitter best known for its roles in reward, motivation, and motor function in the central nervous system, its actions extend beyond neurons and can influence non-neuronal cells via epigenetic mechanisms. An increasing body of literature corroborates that dopamine signaling is important in immune cells, which express dopamine receptors (DRD1-DRD5) as well as the molecular machinery for dopamine synthesis and metabolism. Dopamine can regulate inflammatory activity, cell trafficking, and disease pathology, yet the epigenetic mechanisms underlying these effects remain poorly understood. Here, we show that in primary human monocyte-derived macrophages, dopamine increases DNA methylation at the IL-1{beta} proximal promoter in a DNMT-dependent manner, while concurrently upregulating IL-1{beta} gene expression. Dopamine also increases the expression of key epigenetic regulators, including TET2, HDAC2, and HDAC6, suggesting coordinated changes in both DNA methylation and histone modifications that shape inflammatory transcription. Importantly, baseline dopamine receptor expression and donor demographics, including sex and age, influence the magnitude of these epigenetic responses, highlighting inter-individual variability in macrophage sensitivity to dopaminergic signaling. These findings establish dopamine as a modulator of macrophage inflammation via epigenetic remodeling and provide a mechanistic framework for understanding how peripheral immune cells respond to dopaminergic cues. By linking dopamine signaling, epigenetic regulation, and innate immunity, this work identifies potential targets for therapeutic intervention and supports the use of accessible human immune cells to investigate dopaminergic dysregulation in neuroimmunological disorders.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Brain, Behavior, and Immunity
105 papers in training set
Top 0.1%
18.6%
2
Journal of Neuroinflammation
50 papers in training set
Top 0.1%
10.1%
3
Cell Reports
1338 papers in training set
Top 4%
8.4%
4
The Journal of Immunology
146 papers in training set
Top 0.2%
6.4%
5
eLife
5422 papers in training set
Top 25%
3.6%
6
Frontiers in Immunology
586 papers in training set
Top 2%
3.6%
50% of probability mass above
7
Neuroscience & Biobehavioral Reviews
43 papers in training set
Top 0.2%
2.6%
8
JCI Insight
241 papers in training set
Top 3%
2.1%
9
Scientific Reports
3102 papers in training set
Top 55%
1.8%
10
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.7%
11
Immunology
29 papers in training set
Top 0.4%
1.7%
12
Nature Communications
4913 papers in training set
Top 51%
1.7%
13
Science Translational Medicine
111 papers in training set
Top 2%
1.7%
14
Science Advances
1098 papers in training set
Top 18%
1.7%
15
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 35%
1.5%
16
Biological Psychiatry Global Open Science
54 papers in training set
Top 0.8%
1.3%
17
Immunity
58 papers in training set
Top 3%
1.3%
18
Nature Immunology
71 papers in training set
Top 1%
1.2%
19
Cell Reports Medicine
140 papers in training set
Top 5%
1.2%
20
PLOS Biology
408 papers in training set
Top 14%
1.2%
21
Nature Metabolism
56 papers in training set
Top 2%
0.9%
22
Cell Chemical Biology
81 papers in training set
Top 3%
0.9%
23
iScience
1063 papers in training set
Top 27%
0.9%
24
eBioMedicine
130 papers in training set
Top 4%
0.8%
25
Cell Communication and Signaling
35 papers in training set
Top 1%
0.7%
26
Diabetes
53 papers in training set
Top 0.6%
0.7%
27
Neuron
282 papers in training set
Top 9%
0.7%
28
Science Immunology
81 papers in training set
Top 2%
0.6%
29
Cellular & Molecular Immunology
14 papers in training set
Top 2%
0.6%
30
Journal of Experimental Medicine
106 papers in training set
Top 4%
0.6%